Early, Limited and Late Stage Management of Small Cell Lung Cancer (SCLC)

Authored by Eric Kowalchyk, published on 2026-08-27 23:25:51.0

The algorithm is broadly aligned with contemporary SCLC practice for staging (PET/CT and brain MRI), curative-intent limited-stage management with concurrent chemoradiation, and first-line extensive-stage chemoimmunotherapy with PD-L1 blockade. The inclusion of consolidation durvalumab after chemoradiation for limited-stage SCLC reflects emerging/now practice-changing evidence (ADRIATIC) but exact adoption details may vary by guideline update cycle and regulatory status by jurisdiction. Several nodes are under-specified (radiation details, surveillance intervals, and later-line sequencing), and one node appears internally inconsistent regarding maintenance immunotherapy choices.

  1. All Patients Get Systemic Rx
  2. SCLC Workup
    PET/CT MRI Brain NGS
    • Limited Stage
      • TMT / Radiation
        • Carbo/Etoposide + Radiation (Concurrent, Cycles 2–4)
          • If Responding
            • Durvalumab x 24 Months (ADRIATIC)
              • PCI ± MRI surveillance (case by case basis)
    • Extensive Stage
      • Carbo + Etop + Atezolizumab
        • q2 – MRI
          • Maintenance Atezolizumab or Durvalumab or Atezo/Durva
            • Progression
              • Tarlatamab (DeLLphi-304)
                • Topotecan / Irinotecan / Chemo
                • Clinical Trial
    • Very Early Stage (T1–T2, N0, M0)
      • Surgery / SABR
        • Carbo-Etop x4
          • MRI surveillance
  3. Brain Mets?
    • Symptomatic
      • Steroids
        • Radiation
    • Asymptomatic
      • Systemic
        • q2 – MRI
tosprivacy